CCL2 and ovarian cancer: To test whether the silencing of CCL2 expression in the ovarian cancer cell lines is related to hyper-methylation of CpG dinucleotides, we treated cell lines with 0, 0.5 or 2.0 μM of the methyltransferase inhibitor 5-azacytidine.